Real-world Treatment Patterns and Clinical Outcomes in Epidermal Growth Factor Receptor(EGFR)-Mutant Unresectable Locally Advanced NSCLC: A Retrospective Multi-center Study

The investigators will obtain a cohort of patients from multiple large cancer centers in China and try to unravel the efficacy of "radiotherapy combined with EGFR-TKI", which may provide some evidences for the treatment of stage III-inoperable NSCLC.

Start Date01 Mar 2020

Sponsor / Collaborator

Chinese Academy of Medical Sciences

NCT03529084 / WithdrawnPhase 3

A Randomized, Open-label, Phase III Study of Single Agent Nazartinib Versus Investigator's Choice (Erlotinib or Gefitinib) as First-Line Treatment in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Activating Mutations

This is a phase III, open label, randomized controlled multi-center global study designed to evaluate the safety and efficacy of single agent nazartinib (EGF816) compared with investigator's choice (erlotinib or gefitinib) in patients with locally advanced or metastatic NSCLC who are treatment naïve and whose tumors harbor EGFR activating mutations (L858R or ex19del).

Start Date24 Jul 2018

Sponsor / Collaborator

Novartis Pharmaceuticals Corp.

NCT03516214 / CompletedPhase 1IIT

An Open-label, Multicenter, Phase I Dose-escalation Trial of EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer and Acquired EGFR p.T790M-positive Resistance to 1st or 2nd Generation EGFR TKI Therapy Remark: According to Version V02_0 of the Protocol, Patients May Also be Eligible if EGFR TKI-treatment naïve, EGFR p.T790M-negative at Progression While on EGFR TKI Therapy or After Progression While on Osimertinib Treatment

The aim of this trial is to identify the maximum tolerated dose (MTD)/recommended phase II dose (RP2D), to define pharmacokinetic (PK) parameters and the preliminary efficacy of a continuous treatment with EGF816 and trametinib in locally advanced or metastatic (stage IIIB or IV) lung cancer patients with activating mutations in the epithelial growth factor receptor (EGFR).

Start Date25 Apr 2018

Sponsor / Collaborator

University of Cologne Executive School GmbH

100 Clinical Results associated with Nazartinib

100 Translational Medicine associated with Nazartinib

100 Patents (Medical) associated with Nazartinib

Literatures (Medical) associated with Nazartinib

01 Sep 2024·European Journal of Cancer

Capmatinib plus nazartinib in patients with EGFR-mutated non–small cell lung cancer

Article

Author: Djentuh, Leslie O'Sullivan ; Barlesi, Fabrice ; Abreu, Delvys Rodriguez ; Belli, Riccardo ; Sequist, Lecia V ; Soo, Ross A ; Metro, Giulio ; Jary, Aline ; Glaser, Sabine ; Smith, Nathalie ; Wolf, Jürgen ; Ardizzoni, Andrea ; Giovannini, Monica ; Campelo, Maria Rosario Garcia ; Ponce-Aix, Santiago ; Yang, James Chih-Hsin ; Sprauten, Mette ; Zou, Mike ; Felip, Enriqueta ; Tan, Daniel Sw ; Solomon, Benjamin J ; Cui, Xiaoming ; Lee, Dae Ho

PURPOSEThis phase 1b/2 trial evaluated the efficacy and safety of capmatinib plus nazartinib in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC).METHODSIn phase 1b, patients with progression on first-/second-generation EGFR-TKIs received escalating doses of capmatinib 200-400 mg bid plus nazartinib 50-150 mg qd. Once the MTD/RP2D was declared, phase 2 commenced with patient enrollment into groups according to mutation status and prior lines of treatment: group 1 (fasted; EGFR-TKI resistant; 1-3 prior lines; EGFR^{L858R/ex19del}; any T790M/MET); group 2 (fasted; EGFR-TKI naïve; 0-2 prior lines; de novo T790M+; any MET); group 3 (fasted; treatment-naïve; EGFR^{L858R/ex19del}; T790M-; any MET); group 4 (with food; 0-2 prior lines; EGFR^{L858R/ex19del}; any T790M/MET). Primary endpoints in phase 2 were investigator-assessed overall response rate (ORR) per RECIST v1.1 (groups 1-3), safety, and tolerability of the combination with food (group 4). Efficacy was assessed by T790M and MET status for a subgroup of patients.RESULTSThe RP2D was capmatinib 400 mg bid plus nazartinib 100 mg qd. In phase 2 (n = 144), the ORR was 28.8 %, 33.3 %, 61.7 %, and 42.9 % in groups 1 (n = 52), 2 (n = 3), 3 (n = 47), and 4 (n = 42), respectively. In group 1 +phase 1b RP2D, the ORR was 45.8 %, 26.2 %, 37.9 %, and 32.4 % in MET+ (n = 24), MET- (n = 42), T790M+ (n = 29), and T790M- (n = 34) patients. Most common any-grade treatment-related adverse events (≥25 %; n = 144) were peripheral edema (54.9 %), nausea (41.7 %), diarrhea (34.0 %), and maculopapular rash (25.0 %).CONCLUSIONCapmatinib plus nazartinib showed antitumor activity in patients with EGFR-TKI-resistant, EGFR-mutated NSCLC. The overall safety profile was acceptable.CLINICAL TRIAL REGISTRATIONClinicalTrials.gov NCT02335944.

01 Jul 2024·Heliyon

Characterization of the in vitro metabolic profile of nazartinib in HLMs using UPLC-MS/MS method: In silico metabolic lability and DEREK structural alerts screening using StarDrop software

Article

Author: Attwa, Mohamed W ; Abdelhameed, Ali S ; Kadi, Adnan A

The orally given, irreversible, third-generation inhibitor of the epidermal growth factor receptor (EGFR), known as Nazartinib (EGF816), is now undergoing investigation in Phase II clinical trials conducted by Novartis for Non-Small Cell Lung Cancer. The primary aim of the current research was to establish a rapid, specific, environmentally friendly, and highly versatile UPLC-MS/MS methodology for the determination of nazartinib (NZT) levels in human liver microsomes (HLMs). Subsequently, same approach was used to examine the metabolic stability of NZT. The UPLC-MS/MS method employed in HLMs was validated as stated in the bioanalytical method validation criteria outlined by the US- FDA. The evaluation of the metabolic stability of NZT and the identification of potentially structural alarms were performed using the StarDrop software package that includes the P450 and DEREK software. The calibration curve for NZT showed a linearity in the range from 1 to 3000 ng/mL. The inter-day accuracy and precision exhibited a range of values between -4.33 % and 4.43 %, whereas the intra-day accuracy and precision shown a range of values between -2.78 % and 7.10 %. The sensitivity of the developed approach was verified through the determination of a LLOQ of 0.39 ng/mL. The intrinsic clearance and in vitro half-life of NZT were assessed to be 46.48 mL/min/kg and 17.44 min, respectively. In our preceding inquiry, we have effectively discerned the bioactivation center, denoted by the carbon atom between the unsaturated conjugated system and aliphatic linear tertiary amine. In the context of computational software, making minor adjustments or substituting the dimethylamino-butenoyl moiety throughout the drug design process may increase the metabolic stability and safety properties of new synthesized derivatives. The efficiency of utilizing different in silico software approaches to conserve resources and reduce effort was proved by the outcomes attained from in vitro incubation experiments and the use of NZT in silico software.

01 Apr 2023·Cell Reports

Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors

Article

Author: Zumstein-Mecker, Sabine ; King, Frederick J. ; Meltzer, Jodi ; Delach, Scott ; Mulford, Iain J. ; Engelman, Jeffrey A. ; Tiedt, Ralph ; Caponigro, Giordano ; Stamm, Christelle ; Niederst, Matthew J. ; Porta, Diana Graus ; Kerr, Grainne ; Ainscow, Edward ; Sellers, William R. ; Engstler, Barbara Schacher ; Schnell, Christian ; Golji, Javad ; Labrot, Emma ; Barretina, Jordi ; Wyss, Daniel ; Baltschukat, Sabrina

Anti-tumor efficacy of targeted therapies is variable across patients and cancer types. Even in patients with initial deep response, tumors are typically not eradicated and eventually relapse. To address these challenges, we present a systematic screen for targets that limit the anti-tumor efficacy of EGFR and ALK inhibitors in non-small cell lung cancer and BRAF/MEK inhibitors in colorectal cancer. Our approach includes genome-wide CRISPR screens with or without drugs targeting the oncogenic driver ("anchor therapy"), and large-scale pairwise combination screens of anchor therapies with 351 other drugs. Interestingly, targeting of a small number of genes, including MCL1, BCL2L1, and YAP1, sensitizes multiple cell lines to the respective anchor therapy. Data from drug combination screens with EGF816 and ceritinib indicate that dasatinib and agents disrupting microtubules act synergistically across many cell lines. Finally, we show that a higher-order-combination screen with 26 selected drugs in two resistant EGFR-mutant lung cancer cell lines identified active triplet combinations.

News (Medical) associated with Nazartinib

04 Nov 2022

·www.prnewswire.com

Akeso Completes Enrollment in Phase III Trial of PD-1/VEGF Bispecific Antibody (AK112) Combined with Chemotherapy in EGFR-TKI-resistant nsq-NSCLC

Akeso, Biopharma (9926. HK) ("Akeso") announced the patient enrollment completion for the Phase III clinical trial of Ivonescimab (PD-1/VEGF bi-specific antibody, AK112) combined with chemotherapy for the treatment of EGFR-mutant locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC) who have failed to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment. This trial is a randomized, double-blind, multi-center Phase III clinical trial, which started patient enrollment in end of January 2022, and it has enrolled 320 participants as of the date of this press release. The primary endpoint of the trial is progression-free survival (PFS) assessed by IRRC. This therapy was granted Breakthrough Therapy Designation by the Center for Drug Evaluation, National Medical Products Administration (CDE, NMPA) lately in October 2022. Lung cancer is a malignant tumor with high incidence and high mortality rates worldwide. The incidences of lung cancer around the world and in China have exceeded 2.2 million and 810 thousand respectively in 2020. Non-small cell lung cancer (NSCLC) patients account for 85% of total lung cancer patients, and about 70% of NSCLC patients are diagnosed at advanced stages. In China, nsq-NSCLC accounts for 70% of NSCLC, and about 40%-50% of nsq-NSCLC patients have EGFR mutation. Immunotherapy plus anti-angiogenesis therapy has proved its combination advantages in previous studies worldwide. Lung cancer is one of the mainstream exploration areas of this therapy. AK112 could simultaneously block PD-1 and VEGF targets and has demonstrated favourable safety profile and promising anti-tumor efficacy in ongoing studies conducted by Akeso. AK112 in combination with chemotherapy is expected to provide a novel and effective therapy for the treatment of EGFR-mutated locally advanced or metastatic nsqNSCLC patients who have failed to EGFR-TKI treatment. ABOUT IVONESCIMAB (PD-1/VEGF BI-SPECIFIC ANTIBODY, AK112) Ivonescimab is a first-in-class and the first to enter phase III clinical trial PD-1/VEGF bi-specific antibody independently developed by Akeso. Engineered with our unique Tetrabody technology, Ivonescimab blocks PD-1 binding to PD-L1 and PD-L2, and blocks VEGF binding to VEGF receptors. PD-1 antibody combined with VEGF blocking agents have shown robust efficacy in various tumor types (including renal cell carcinoma, non-small cell lung cancer and hepatocellular carcinoma). In view of the co-expression of VEGF and PD-1 in the tumor microenvironment, Ivonescimab, as a single agent to block these two targets, may block these two pathways more effectively and enhance the antitumor activity, as compared to combination therapy. Currently, Akeso is conducting a phase III clinical trial of AK112 monotherapy versus Pembrolizumab monotherapy as the first-line treatment for NSCLC patients with positive PD-L1 expression. In addition, a phase III clinical trial of AK112 plus chemotherapy versus chemotherapy in EGFR mutated advanced non-squamous NSCLC that failed in prior EGFR-TKI therapy is ongoing. AK112 has been investigated in multiple clinical trials for various stages treatment of indications including non-small cell lung cancer and small cell lung cancer.

AntibodyBreakthrough TherapyPhase 3

16 Sep 2022

·www.prnewswire.com

J INTS BIO's Novel Oral 4th Generation EGFR-TKI 'JIN-A02' effective against both cis and trans isomers of C797S mutations - ESMO 2022

SEOUL, South Korea, Sept. 15, 2022 /PRNewswire/ -- J INTS BIO announced the poster presentation of its novel, orally administered 4th generation EGFR-TKI 'JIN-A02' at the ESMO 2022, that showed high potency of JIN-A02 against both cis and trans isomers of C797S mutation. This year's edition of the European Society for Medical Oncology Congress (ESMO 2022) was held in Paris, France from 9th to 13th September. Continue Reading Professor Cho, Byoung Chul, poster presentation of further preclinical data of its Novel Oral 4th Generation EGFR-TKI ‘JIN-A02’ at the 2022 European Society for Medical Oncology Congress in Paris, France (ESMO 2022) Even though EGFR-TKI have improved treatment outcomes of patients with EGFR mutant NSCLC, resistance inevitably emerges with disease progression and often with CNS metastasis. C797S mutation is one of the most common on-target resistance mutation after the use of 3rd generation TKIs such as Osimertinib. 'JIN-A02' is a novel 4th generation EGFR-TKI, which is highly selective and potent against C797S double and triple mutations, with high BBB penetrance and intracranial efficacy. The allelic context in which this C797S mutation is acquired, cis or trans isomers, have significant implications for treatment outcomes. This is especially so when C797S positive tumor are in cis form together with T790M mutation. In such situations, there are no available treatments. J INTS BIO believes that JIN-A02 will be pivotal in the treatment of patients with EGFR mutant NSCLC harboring C797S double or triple mutations, regardless of allelic context. And the company is expecting the Phase I/IIa clinical study for JIN-A02 to start recruitment before the end of this year. About J INTS BIO J INTS BIO is a bio company specialized in developing innovative anti-cancer and orphan drugs to realize the goal of changing lives and improving health for patients around the world. J INTS BIO's teams have prior multi-year experience in multinational pharmaceutical companies and CROs and track records in medical, regulatory affairs, drug discovery and development. About 'JIN-A02' 'JIN-A02' is a novel orally administered 4th Generation EGFR TKI targeting C797S mutations in NSCLC. Although 1st, 2nd, and 3rd Generation EGFR TKIs have been used with some success, recurrence occurs in most patients including 3rd Generation TKIs such as Osimertinib. Currently, there are no approved therapies for patients who developed EGFR C797S mutations due to the use of 3rd Generation EGFR TKIs and with the high propensity of these cancers to metastasize to the brain, there is an urgent need to develop an effective drug with high blood-brain barrier permeability. 'JIN-A02', a novel oral EGFR TKI, which is effective against C797S double and triple mutations and have a high brain penetrance, is therefore expected to become the most promising Best-in-Class 4th-generation EGFR TKI in NSCLC patients with limited or no viable treatment options. SOURCE J INTS BIO

Pre-Clinical Data

25 Aug 2022

·www.prnewswire.com

Alpha Biopharma Announces Completion of its EVEREST Phase II/III Clinical Study of Zorifertinib in Non-Small Cell Lung Cancer Patients with Central Nervous System Metastases

SHANGHAI, Aug. 24, 2022 /PRNewswire/ -- Alpha Biopharma, a developer of innovative drugs, announces the completion of last patient last visit (LPLV) in its international, multicenter EVEREST phase II/III clinical study of Zorifertinib, a next-generation EGFR-TKI, in first line patients with advanced EGFRm+ non-small cell lung cancer (NSCLC) with central nervous system (CNS) metastases. Topline data from this MRCT study are expected around the end of 2022, at which time Alpha Biopharma could submit a New Drug Application (NDA) to the National Medical Products Administration (NMPA). As the international leading principal investigator (PI) of EVEREST study, Professor Yilong Wu, President of the Chinese Thoracic Oncology Group (CTONG), said: "EVEREST study is an international, multicenter, phase II/III randomized clinical study. It is also the only large-scale prospective international multicenter clinical study worldwide for first line EGFRm+ NSCLC patients with CNS metastases to date. It was carried out in 55 study sites located in Chinese mainland, Taiwan, South Korea, and Singapore, with a total enrollment of 492 patients. The clinical and preclinical data of Zorifertinib have shown its high blood-brain barrier (BBB) penetration, anti-tumor activity in metastatic CNS lesions, overall efficacy in both CNS and extra-cranial diseases, and similar safety profile as other EGFR-TKI drugs. If approved, it is expected to provide a valuable choice for treatment of EGFRm+ NSCLC patients with CNS metastases. As the name EVEREST suggests, the study sponsor and investigators are dedicated to solving important unmet clinical needs." Professor Jie Wang, Director of Oncology Department of Cancer Hospital Chinese Academy of Medical Sciences, and co-leading PI of EVEREST study, said: "Lung cancer with CNS metastases has always been a challenging problem and leading cause of death for these patients. Zorifertinib is a next-generation, high-potent EGFR-TKI drug targeting sensitive mutations of exon 19 deletion or L858R in EGFR gene with good exposure in CNS lesions. It is not a substrate of efflux transporter P-gp and BCRP, thus not only capable of fully passing through BBB, but also maintaining high drug exposure in the brain tissue and cerebrospinal fluid. It was intentionally designed to optimize its physicochemical and biochemical properties meet the requirements of CNS penetration, which has been proven to be the case in this and prior clinical studies. We look forward to the finale data readout and if positive, a direly needed treatment for these patients." Dr. Ruilin Song, Executive President of China Pharmaceutical Innovation and Research Development Association, said: "In the past three years, the COVID-19 pandemic in some regions of China has brought great challenges to innovative biotech companies. Many clinical study sites faced challenges in terms of regional lockdown, logistics, and clinical operations. However, the clinical development team at Alpha Biopharma and investigators worked together to overcome difficulties to achieve the key milestones of the EVEREST study. They diligently communicated with study sites to come up with solutions, paid full attention to the safety of the subjects and the quality of the trial data while ensuring the uninterrupted treatment of the subjects. In recognizing this pivotal milestone of EVEREST study completion, we would like to express sincere respect for the efforts of all relevant personnel involved in the study and wish Zorifertinib a smooth NDA submission. We are a step closer to bringing new hope to patients with CNS metastases of EGFRm+ NSCLC." About Zorifertinib Zorifertinib is a potent, oral, reversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR-TKI) activating mutation (L858R and Exon19Del). EGFR is widely expressed in human epidermal cells and stromal cells and is highly expressed in a variety of human malignancies, such as NSCLC. EGFR gene mutation will cause excessive epidermal growth factor receptors on the cell membrane surface, accelerate the abnormal growth and division of cells, and eventually lead to tumorigenesis. CNS metastases is common in EGFRm+ NSCLC patients and accompanied with poor prognosis of earlier disease progression, shorter survival, and lower quality of life. The BBB significantly increases the difficulty of drug penetration into CNS, which allows the CNS to be a refuge for lung cancer cells. Zorifertinib is a new-generation EGFR-TKI specifically designed to fully penetrate the BBB to target brain metastases. Zorifertinib is in late-stage clinical studies and has global intellectual property protection. About Alpha Biopharma Alpha Biopharma is a late-stage biopharmaceutical company focused on developing potential new therapies for cancer's unmet medical need. Founded in 2017, the Company has advanced its EGFRm+ targeted small molecule drug Zorifertinib to its Phase II/III trial (EVEREST) to treat NSCLC patients with brain metastases. In addition, Alpha Biopharma has initiated an IIT clinical study of an NK cell therapy targeting AML and is developing CAR-T cell therapy that it licensed from Wugen Inc. for the Greater China region. Alpha BioPharma's experienced team, leading clinicians, and collaborators integrate their oncology expertise to find innovative solutions to transform the lives of cancer patients. SOURCE ALPHA BIOPHARMA

Innovative DrugCell TherapySmall molecular drug

100 Deals associated with Nazartinib

External Link

KEGG	Wiki	ATC	Drug Bank
D11430	-	-	DB16250

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Locally Advanced Lung Non-Small Cell Carcinoma	Phase 2	-	Novartis Pharmaceuticals Corp.	24 Jul 2018
Advanced Lung Non-Small Cell Carcinoma	Phase 2	US	Novartis Pharmaceuticals Corp.	06 Jun 2014
Advanced Lung Non-Small Cell Carcinoma	Phase 2	DE	Novartis Pharmaceuticals Corp.	06 Jun 2014
Advanced Lung Non-Small Cell Carcinoma	Phase 2	KR	Novartis Pharmaceuticals Corp.	06 Jun 2014
Advanced Lung Non-Small Cell Carcinoma	Phase 2	CA	Novartis Pharmaceuticals Corp.	06 Jun 2014
Advanced Lung Non-Small Cell Carcinoma	Phase 2	TW	Novartis Pharmaceuticals Corp.	06 Jun 2014
Advanced Lung Non-Small Cell Carcinoma	Phase 2	NL	Novartis Pharmaceuticals Corp.	06 Jun 2014
Advanced Lung Non-Small Cell Carcinoma	Phase 2	SG	Novartis Pharmaceuticals Corp.	06 Jun 2014
Advanced Lung Non-Small Cell Carcinoma	Phase 2	ES	Novartis Pharmaceuticals Corp.	06 Jun 2014
Advanced Lung Non-Small Cell Carcinoma	Phase 2	JP	Novartis Pharmaceuticals Corp.	06 Jun 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02335944 (phase 1b/2 trial, Pubmed)	Phase 1/2	EGFR-mutated non-small Cell Lung Cancer EGFR-TKI resistant \| EGFR-TKI naïve \| T790M+ ... View more	144	Capmatinib 400 mg bid plus Nazartinib 100 mg qd	(gudkbjfrez) = qwbweqxzhc oqzyjyoayy (sgwkjuzdzu )	Positive	01 Sep 2024
NCT02108964 (Pubmed) Manual	Phase 2	EGFR-mutated non-small Cell Lung Cancer First line EGFR Mutation	45	Nazartinib	(sqxgrexudf) = nzbpuiuiyp hslwskubbt (ozhgmjfkhp, 53 - 82) View more	Positive	07 Jul 2022
NCT02108964 (Pubmed) Manual	Phase 2		45	Nazartinib (brain metastases)	(sqxgrexudf) = dyhjjzymvt hslwskubbt (ozhgmjfkhp, 41 - 87) View more	Positive	07 Jul 2022
NCT02323126 (GEOMETRY mono-1, CTgov)	Phase 2	EGFR-mutated non-small Cell Lung Cancer	64	EGF816+Nivolumab (Nivolumab and EGF816)	grrywiogqz(yakdejervz) = tuoxarjdxp petgwddtqt (eubupwhrjh, stxakfqrev - ajccxqawlz) View more	-	15 Jun 2021
NCT02323126 (GEOMETRY mono-1, CTgov)	Phase 2	EGFR-mutated non-small Cell Lung Cancer	64	Nivolumab+INC280 (Nivolumab and INC280, High cMet)	grrywiogqz(yakdejervz) = tvtvlrsuna petgwddtqt (eubupwhrjh, uiamwhnxxn - tnxvohowvf) View more	-	15 Jun 2021
NCT02335944 (ESMO2020) Manual	Phase 2	EGFR-mutated non-small Cell Lung Cancer MET Positive	115	capmatinib+nazartinib (Group 1)	(bhkxfwiuiv) = jrrnqobvsy ekffnyxyfx (lilatskhpg, 17.1 - 43.1) View more	Positive	17 Sep 2020
NCT02335944 (ESMO2020) Manual	Phase 2	EGFR-mutated non-small Cell Lung Cancer MET Positive	115	capmatinib+nazartinib (Group 1 + Ph 1b RP2D + MET+)	(bhkxfwiuiv) = bdvhczqnox ekffnyxyfx (lilatskhpg, 23.2 - 65.5) View more	Positive	17 Sep 2020
NCT02108964 (Pubmed) Manual	Phase 1	EGFR-mutated non-small Cell Lung Cancer EGFR Mutation	180	nazartinib	(uatqkeqsut) = qlrvztpxzr odcmvsvzuk (dqkxbvfcic ) View more	Positive	01 Jun 2020
NCT02108964 (ASCO2020)	Phase 2	Solid tumor \| Advanced Lung Non-Small Cell Carcinoma	45	Nazartinib 150 mg	cyeztlriad(cplknwygvi) = 27% bunfrrqwcu (vyhhvhuynw ) View more	Positive	25 May 2020
EUCTR2013-004482-14-BE \| NCT02108964 (ESMO2018)	Phase 2	EGFR-mutated non-small Cell Lung Cancer	45	Nazartinib 150 mg QD	(ffjcbhflds) = mlyqchxbgo jorsimupvs (vwhpkezurd, 49% - 78%) View more	Positive	19 Oct 2018
NCT02108964 (ASCO2018)	Phase 2	Solid tumor \| Advanced Lung Non-Small Cell Carcinoma	40	Nazartinib 150 mg QD	(ohjsxcpciy) = Gr 3 AEs occurred in 10/40 (25%) pts, most commonly (≥5%) maculopapular rash in 4/40 (10%) pts and hypokalemia in 2/40 (5%) pts; there were no Gr 4 AEs eihfqkwexn (svttazakso ) View more	Positive	01 Jun 2018
NCT02108964 (ASCO2017)	Phase 1/2	Non-Small Cell Lung Cancer	9	EGF816	(ylqaxrntqp) = sxoupwouat jpxlajzxks (alsffuodfr ) View more	-	30 May 2017
NCT02108964 (ASCO2016)	Phase 1	EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma	132	EGF816	(ebpdqmsogt) = 6% kemjohyqsl (orpagdrtcn ) View more	Positive	20 May 2016

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis